Search
Bristol-Myers Squibb Co
BMYAdd to Watchlist
59.365USD
+1.785+3.10%
Close 07/13, 16:00（ET）Quotes delayed by 15 min
121.22BMarket Cap
16.62P/E TTM
More Details of Bristol-Myers Squibb Co Company
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Bristol-Myers Squibb Co Info
Ticker SymbolBMY
Company nameBristol-Myers Squibb Co
IPO dateMar 17, 1980
CEOBoerner (Christopher S)
Number of employees34100
Security typeOrdinary Share
Fiscal year-endMar 17
AddressRoute 206 And Province Line Road
CityPRINCETON
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code08543
Phone16092524621
Websitehttps://www.bms.com
Ticker SymbolBMY
IPO dateMar 17, 1980
CEOBoerner (Christopher S)
Company Executives of Bristol-Myers Squibb Co
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
146.89K
+56.50%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
34.08K
+60.04%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
28.79K
+5.61%
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
28.48K
+2.00%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
13.13K
+15.73%
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
1.20K
--
Mr. Michael R. (Mike) McMullen
Mr. Michael R. (Mike) McMullen
Independent Director
Independent Director
1.00K
--
Mr. Peter J. (Pete) Arduini
Mr. Peter J. (Pete) Arduini
Independent Director
Independent Director
--
--
Mr. Theodore R. Samuels, II
Mr. Theodore R. Samuels, II
Lead Independent Director
Lead Independent Director
--
--
Dr. Karen H. Vousden, Ph.D.
Dr. Karen H. Vousden, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
146.89K
+56.50%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
34.08K
+60.04%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
28.79K
+5.61%
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
28.48K
+2.00%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
13.13K
+15.73%
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
1.20K
--
FAQs
Who are the top five shareholders of Bristol-Myers Squibb Co?
The top five shareholders of Bristol-Myers Squibb Co are: Dr. Christopher S. (Chris) Boerner, Ph.D.
How many institutions hold shares of Bristol-Myers Squibb Co (BMY)?
As of 2026Q1, 4176 institutions hold shares of Bristol-Myers Squibb Co, with a combined market value of approximately 1.72B, accounting for 84.35% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -11351598.00.
What is the biggest source of revenue for Bristol-Myers Squibb Co?
In 2026Q1, the Eliquis business generated the highest revenue for Bristol-Myers Squibb Co, amounting to 14.44B and accounting for 29.97% of total revenue.